jueves, 16 de agosto de 2012

WHO Pharmaceuticals Newsletter No. 4, 2012


Contenido

Regulatory Matters

Calcitonin- containing medicines ..................................................................... 4

Candesartan ................................................................................................ 4

Dabigatran etexilate ..................................................................................... 5

Dalfampridine .............................................................................................. 5

Denosumab ................................................................................................. 5

Doripenem .................................................................................................. 6

Febuxostat .................................................................................................. 6

Tolperisone ................................................................................................. 6

Trimetazidine-containing medicines ................................................................ 7

Hepatitis B Immune Globulin (Human) Injection ............................................... 8

Immune Globulin Intravenous (Human) ........................................................... 8

Oral tacrolimus ............................................................................................ 8


Safety of medicines

Bisphosphonates, corticosteroids, angiogenesis inhibitors and

denosumab ................................................................................................ 10

Butterbur ................................................................................................... 10

Caffeine citrate ........................................................................................... 10

Non-steroidal anti-inflammatory drugs....................................................... 10

Peanut Oil .................................................................................................. 11

Serotonergic medicines ................................................................................ 11

Statins and ciclosporin ................................................................................. 12

Tacrolimus ointment .................................................................................... 12

Zolpidem ................................................................................................... 12

Signal

Dronedarone, hyperthyroidism and decreased Thyroid Stimulating

Hormone.................................................................................................... 14

Mometasone and Arrhythmia ........................................................................ 20

Feature

Paediatric morphine dosages......................................................................... 26

Ninth meeting of the WHO Advisory Committee on Safety of Medicinal

Products (ACSoMP) ...................................................................................... 29       proximamente en   http://www.who.int/medicines/publications/newsletter/en/